Netarsudil mesylate

Drug Profile

Netarsudil mesylate

Alternative Names: AR-13224; AR13324; Rhopressa

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Rho-associated kinase inhibitors; Transforming growth factor beta type II receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension
  • Preclinical Neurological disorders

Most Recent Events

  • 23 Dec 2016 Aerie Pharmaceuticals plans to resubmit NDA to the US FDA for Netarsudil mesylate for Glaucoma and Ocular hypertension, at the end of the first quarter of 2017
  • 02 Nov 2016 Aerie Pharmaceutical completes a phase II trial in Glaucoma and Ocular hypertension in USA (NCT02874846)
  • 27 Oct 2016 Regulatory submission withdrawn for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top